Global /China /Healthcare /Drug Manufacturers - General /2496

Wuhan YZY Biopharma Co., Ltd.

2496

• SHEK: 2496 • Delayed

4.60HKD -4.2%

0.5870 USD

As of 21 June 2026, Wuhan YZY Biopharma Co., Ltd. has a market cap of $118.71M USD, ranking #24364 globally and #5881 in China. It ranks #2179 in the Healthcare sector, and #789 in the Drug Manufacturers - General industry.

Global Rank

24364

Country Rank

5881

Sector Rank

2179

Industry Rank

789

Key Stats

Market Cap

$118.71MUSD

930.48M HKD

Enterprise Value

$122.67MUSD

961.29M HKD

Revenue (TTM)

$9.49MUSD

74.4M HKD

EBITDA (TTM)

-$10.9MUSD

-85.42M HKD

Net Income (TTM)

-$12.03MUSD

-94.29M HKD

EBITDA Margin

-115%

Profit Margin

-127%

PS Ratio

12.5

PB Ratio

-15.8

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Pengfei Zhou open_in_new

Employees

106

Founded

2010

Website

yzybio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.2%	-0.4%	16%	-38%	-32%	-40%	2.1%	-76%	-76%

News

Markets

Exchange	Ticker	Price	Quotes
Hong Kong Stock Exchange (SHEK / HKEX) MIC: XHKG PRIMARY	2496 武汉友芝友生物制药股份有限公司 Ordinary Shares - Class H ISIN: CNE1000063C4 Shares Out.: Shares Outstanding: 179.479M¹ Shares Float: 43.017M² TV: TradingView: HKEX: 2496 SA: Stock Analysis: HKG: 2496 YF: Yahoo Finance: 2496.HK GF: Google Finance: HKG: 2496 BA: Barron's: 2496 MS: Morningstar: XHKG: 02496	4.60 HKD	TV: TradingView: HKEX: 2496 SA: Stock Analysis: HKG: 2496 YF: Yahoo Finance: 2496.HK GF: Google Finance: HKG: 2496 BA: Barron's: 2496 MS: Morningstar: XHKG: 02496

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Wuhan YZY Biopharma Co., Ltd.

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. was founded in 2010 and is headquartered in Wuhan, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$54.0B 364.89B CNY 45K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.78B 336.36B CNY 42K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.51B 223.48B HKD 24K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 16K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.56B 111.89B CNY 14K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 13K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 642K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 461K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 304K%	97.4	United States
Roche Holding AG SIX: RO	$318.3B 256.25B CHF 268K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$284.64B 215.59B GBP 240K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 231K%	15.1	United States

chevron_leftBack